How is venture philanthropy revolutionizing Alzheimer's drug discovery? We sit down with Karen Harris, CFO at the Alzheimer's Drug Discovery Foundation, to explore their game-changing approach to funding early-stage research. With $370M+ awarded to 765+ programs globally, the ADDF operates like a VC firm—using convertible debt and preferred equity to accelerate breakthrough treatments. Topics: Venture philanthropy vs traditional grants Shift from amyloid to combination therapies Blood-based biomarkers & precision medicine NIH funding cuts impact on research ecosystem Karen brings 20+ years investment banking experience to discuss how strategic capital is changing Alzheimer's research.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related